Clinical trial · no report yet · Phase 3
NCT01730937
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
- NCT01730937 ↗
- Completed
- Radiation Therapy Oncology Group
- 118 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 103 | |
| YouTube | 6 | |
| Podcasts | 6 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
- Interventions
- Sorafenib; stereotactic body radiation therapy
- Arms
- Sorafenib Alone · Active comparator
- SBRT followed by Sorafenib · Experimental
- Enrollment
- 193
- Primary outcomes
- Overall Survival
- Sponsor
- Radiation Therapy Oncology Group with National Cancer Institute (NCI), NRG Oncology
- Start
- Apr 2013
- Primary completion
- Jul 1, 2022
- Results posted
- Yes
- Registry record
- NCT01730937 · updated Jan 28, 2026
Publications
linked from the registry- Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD, Williams TM, Hosni A, Chen E, Noonan AM, Koay EJ, Sinha R, Lock MI, Ohri N, Dorth JA, Delouya G, Swaminath A, Moughan J, Crane CH. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Feb 1;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403. PubMed 39699905